Ionis Pharmaceuticals (IONS) Financials

Ionis Pharmaceuticals logo
$28.01 -1.05 (-3.61%)
Closing price 04:00 PM Eastern
Extended Trading
$28.26 +0.24 (+0.87%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Ionis Pharmaceuticals

Annual Income Statements for Ionis Pharmaceuticals

This table shows Ionis Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-88 -60 0.35 274 278 -444 -29 -270 -366 -454 -381
Consolidated Net Income / (Loss)
-88 -60 -11 215 287 -480 -29 -270 -366 -454 -381
Net Income / (Loss) Continuing Operations
-88 -60 -11 215 287 -480 -29 -270 -366 -454 -381
Total Pre-Tax Income
-88 -57 -17 -76 339 -135 -29 -258 -334 -460 -380
Total Operating Income
-76 -20 31 -61 366 -172 -30 -410 -354 -475 -382
Total Gross Profit
284 373 514 598 1,118 717 800 573 779 694 928
Total Revenue
284 373 514 600 1,123 729 810 587 788 705 944
Operating Revenue
284 373 514 600 1,123 729 810 587 788 705 944
Total Cost of Revenue
0.00 0.00 0.00 1.82 4.38 12 11 14 9.13 11 16
Operating Cost of Revenue
- 0.00 0.00 1.82 4.38 12 11 14 9.13 11 16
Total Operating Expenses
359 393 483 659 752 889 830 983 1,132 1,169 1,309
Selling, General & Admin Expense
37 49 108 245 287 354 186 150 233 267 394
Research & Development Expense
322 344 375 415 466 535 643 833 900 902 916
Total Other Income / (Expense), net
-12 -37 -48 -15 -27 38 1.04 152 20 15 2.08
Interest Expense
37 43 45 45 79 9.51 9.35 8.12 81 90 91
Interest & Investment Income
25 5.47 8.18 30 52 47 20 18 87 104 108
Other Income / (Expense), net
0.00 0.00 -11 -0.18 -0.69 -0.06 -9.76 142 14 1.33 -15
Income Tax Expense
0.37 2.93 -5.98 -291 52 345 -0.55 12 32 -6.17 1.79
Basic Earnings per Share
($0.74) ($0.50) $0.15 $2.09 $2.00 ($3.18) ($0.20) ($1.90) ($2.56) ($3.04) ($2.38)
Weighted Average Basic Shares Outstanding
119.72M 120.93M 124.02M 132.32M 140.00M 139.61M 141.02M 141.85M 143.19M 149.51M 160.01M
Diluted Earnings per Share
($0.74) ($0.50) $0.15 $2.07 $1.90 ($3.18) ($0.20) ($1.90) ($2.56) ($3.04) ($2.38)
Weighted Average Diluted Shares Outstanding
119.72M 120.93M 126.10M 134.06M 153.16M 139.61M 141.02M 141.85M 143.19M 149.51M 160.01M
Weighted Average Basic & Diluted Shares Outstanding
119.72M 120.20M 4.30M 131M 138.70M 140.86M 141.69M 142.95M 145.75M 158.96M 165.19M

Quarterly Income Statements for Ionis Pharmaceuticals

This table shows Ionis Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-143 -66 -140 -104 -147 124 -129 -229 -93 -115 -110
Consolidated Net Income / (Loss)
-143 -66 -140 -104 -147 124 -129 -229 -93 -115 -110
Net Income / (Loss) Continuing Operations
-143 -66 -140 -103 -147 124 -129 -229 -93 -115 -110
Total Pre-Tax Income
-143 -66 -144 -107 -147 124 -128 -228 -92 -113 -110
Total Operating Income
-150 -66 -149 -111 -147 140 -160 -214 -117 -102 -131
Total Gross Profit
117 221 133 223 130 448 154 195 243 265 239
Total Revenue
119 225 134 227 132 452 157 203 246 268 243
Operating Revenue
119 225 134 227 132 452 157 203 246 268 243
Total Cost of Revenue
2.15 4.16 1.07 3.83 1.46 4.15 2.34 7.96 2.98 2.74 3.32
Operating Cost of Revenue
2.15 4.16 1.07 3.83 1.46 4.15 2.34 7.96 2.98 2.74 3.32
Total Operating Expenses
267 287 281 334 277 308 315 410 361 368 370
Selling, General & Admin Expense
53 65 62 88 76 91 97 130 150 150 154
Research & Development Expense
214 222 220 245 201 217 218 280 210 217 216
Total Other Income / (Expense), net
6.79 -0.11 4.56 2.44 0.04 -16 32 -13 25 -11 21
Interest Expense
22 23 23 23 23 23 22 23 22 22 8.76
Interest & Investment Income
29 22 27 26 23 6.38 54 26 48 10 29
Other Income / (Expense), net
0.28 0.61 0.14 -1.04 0.47 0.10 0.36 -16 -0.46 0.99 0.28
Income Tax Expense
0.08 0.06 -3.62 -2.69 0.12 -0.02 0.21 1.48 0.22 1.26 -0.14
Basic Earnings per Share
($0.98) ($0.45) ($0.95) ($0.66) ($0.93) $0.78 ($0.80) ($1.43) ($0.56) ($0.69) ($0.66)
Weighted Average Basic Shares Outstanding
145.54M 145.96M 148.59M 149.51M 158.74M 159.14M 159.77M 160.01M 164.87M 165.42M 166.21M
Diluted Earnings per Share
($0.98) ($0.45) ($0.95) ($0.66) ($0.93) $0.70 ($0.80) ($1.35) ($0.56) ($0.69) ($0.66)
Weighted Average Diluted Shares Outstanding
145.54M 145.96M 148.59M 149.51M 158.74M 182.33M 159.77M 160.01M 164.87M 165.42M 166.21M
Weighted Average Basic & Diluted Shares Outstanding
145.97M 146.21M 157.90M 158.96M 159.16M 159.39M 161.97M 0.00 165.26M 166.18M 166.55M

Annual Cash Flow Statements for Ionis Pharmaceuticals

This table details how cash moves in and out of Ionis Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-14 -44 45 149 404 -286 472 -593 123 -157 129
Net Cash From Operating Activities
21 -112 174 603 346 36 31 -274 -308 -501 -269
Net Cash From Continuing Operating Activities
21 -112 174 603 346 36 31 -274 -308 -501 -269
Net Income / (Loss) Continuing Operations
-88 -60 -11 215 287 -480 -29 -270 -366 -454 -381
Consolidated Net Income / (Loss)
-88 -60 -11 215 287 -480 -29 -270 -366 -454 -381
Depreciation Expense
6.98 7.48 6.71 11 13 13 15 14 10 9.61 10
Amortization Expense
41 40 45 36 -1.09 19 27 21 -10 -19 -4.14
Non-Cash Adjustments To Reconcile Net Income
41 78 97 180 215 202 131 -47 136 171 158
Changes in Operating Assets and Liabilities, net
20 -178 37 161 -168 281 -114 7.57 -77 -209 -51
Net Cash From Investing Activities
-60 57 -358 -930 -41 274 195 -263 -214 -134 -278
Net Cash From Continuing Investing Activities
-60 57 -358 -930 -41 274 195 -263 -214 -134 -278
Purchase of Property, Plant & Equipment
-12 -12 -38 -18 -31 -35 -12 -16 -24 -45 -51
Acquisitions
- - - - -5.38 -5.93 -5.95 -4.38 -4.18 -5.06 -5.64
Purchase of Investments
-493 -301 -880 -1,795 -1,957 -1,570 -1,131 -1,486 -1,771 -1,853 -1,919
Sale and/or Maturity of Investments
420 365 557 883 1,952 1,886 1,344 989 1,585 1,769 1,698
Net Cash From Financing Activities
25 11 229 476 100 -597 246 -55 644 478 676
Net Cash From Continuing Financing Activities
25 11 229 476 100 -597 246 -55 644 478 676
Repayment of Debt
-9.06 -7.07 -3.60 0.00 -23 0.00 -335 -51 -502 -45 -287
Issuance of Debt
8.50 4.00 60 0.00 110 0.00 633 0.00 575 0.00 770
Issuance of Common Equity
25 13 255 476 176 52 101 6.37 49 523 193
Other Financing Activities, net
0.40 1.86 -80 0.00 -128 -13 -153 -11 522 0.00 0.00
Cash Interest Paid
6.80 7.31 8.04 9.59 9.87 6.25 4.78 2.90 6.51 11 11
Cash Income Taxes Paid
- - 0.00 0.00 9.04 26 0.04 5.01 48 -5.62 -0.64

Quarterly Cash Flow Statements for Ionis Pharmaceuticals

This table details how cash moves in and out of Ionis Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-50 -55 41 -93 22 33 41 33 -199 177 -54
Net Cash From Operating Activities
-150 -120 -115 -116 -151 151 -131 -138 -793 566 -179
Net Cash From Continuing Operating Activities
-150 -120 -115 -116 -151 151 -131 -138 -793 566 -179
Net Income / (Loss) Continuing Operations
-143 -66 -140 -104 -147 124 -129 -229 -93 -115 -110
Consolidated Net Income / (Loss)
-143 -66 -140 -104 -147 124 -129 -229 -93 -115 -110
Depreciation Expense
2.55 2.47 2.36 2.24 2.23 2.27 2.26 3.26 3.30 3.43 3.60
Amortization Expense
-4.49 -5.10 -4.33 -4.75 -2.30 -1.04 -1.19 0.38 0.31 2.66 3.09
Non-Cash Adjustments To Reconcile Net Income
40 43 36 52 37 2.56 1.51 64 -606 696 25
Changes in Operating Assets and Liabilities, net
-46 -94 -8.46 -61 -41 24 -5.41 24 -98 -21 -101
Net Cash From Investing Activities
76 62 -341 68 170 -120 91 -420 537 23 100
Net Cash From Continuing Investing Activities
76 62 -341 68 170 -120 91 -420 537 23 100
Purchase of Property, Plant & Equipment
-4.49 -6.23 -9.06 -25 -13 -12 -5.27 -21 -22 -16 -13
Acquisitions
-1.24 -14 13 -2.55 -0.65 -1.96 -1.66 -1.37 -1.49 -2.15 -1.50
Purchase of Investments
-519 -285 -715 -334 -311 -492 -324 -792 -193 -320 -193
Sale and/or Maturity of Investments
601 368 371 430 495 386 422 395 753 362 307
Net Cash From Financing Activities
24 2.56 496 -44 2.20 1.25 81 591 57 -412 26
Net Cash From Continuing Financing Activities
24 2.56 496 -44 2.20 1.25 81 591 57 -412 26
Repayment of Debt
-0.04 -0.04 -0.05 -45 -0.04 -0.04 -0.04 -287 -0.04 -433 -0.04
Issuance of Common Equity
24 2.60 496 0.43 2.24 1.29 81 108 57 20 26
Effect of Exchange Rate Changes
-0.11 -0.02 - - 0.23 0.60 -0.08 - - - -0.01
Cash Interest Paid
0.10 5.47 0.15 5.16 0.09 5.12 0.19 5.38 0.09 5.12 2.61
Cash Income Taxes Paid
0.01 1.98 0.08 -7.69 -0.40 0.02 -0.28 0.02 -0.01 1.21 2.59

Annual Balance Sheets for Ionis Pharmaceuticals

This table presents Ionis Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
948 912 1,323 2,668 3,233 2,390 2,612 2,534 2,990 3,004 3,524
Total Current Assets
837 798 1,169 2,208 2,721 2,131 2,345 2,203 2,642 2,620 2,991
Cash & Equivalents
129 85 130 279 683 398 869 276 399 242 372
Short-Term Investments
675 581 893 1,805 1,816 1,495 1,246 1,710 1,932 2,056 2,305
Accounts Receivable
- - - - - - - - - 92 66
Inventories, net
6.90 7.49 9.98 8.58 18 22 25 22 7.44 13 10
Other Current Assets
15 17 136 115 203 216 205 194 303 218 237
Plant, Property, & Equipment, net
90 93 122 132 154 181 178 74 71 94 123
Total Noncurrent Assets
21 22 32 328 359 78 89 257 277 289 410
Other Noncurrent Operating Assets
1.35 1.33 10 13 28 50 89 257 277 289 410
Total Liabilities & Shareholders' Equity
948 912 1,323 2,668 3,233 2,390 2,612 2,534 2,990 3,004 3,524
Total Liabilities
747 813 957 1,481 1,549 1,646 1,840 1,961 2,603 2,415 3,035
Total Current Liabilities
149 134 244 280 273 599 241 312 448 309 782
Short-Term Debt
- - - 14 0.00 309 - 0.00 44 0.00 432
Accounts Payable
28 21 25 29 16 17 12 18 26 43 28
Accrued Expenses
28 36 67 48 67 90 89 140 148 108 106
Current Deferred Revenue
67 51 125 160 118 108 98 91 151 79 74
Current Deferred & Payable Income Tax Liabilities
- - - 0.86 33 1.32 0.04 6.25 2.15 0.03 2.71
Current Employee Benefit Liabilities
16 24 25 29 37 66 39 49 68 70 116
Other Current Liabilities
9.03 1.19 1.62 - 2.03 7.30 3.53 7.54 8.83 9.28 11
Total Noncurrent Liabilities
598 679 714 1,200 1,276 1,048 1,599 1,649 2,155 2,106 2,265
Long-Term Debt
389 501 593 628 770 600 1,221 1,183 1,230 1,245 1,319
Capital Lease Obligations
- - - - - - 19 179 171 162 262
Noncurrent Deferred Revenue
134 91 108 567 490 424 352 288 241 157 92
Other Noncurrent Operating Liabilities
75 87 13 4.91 16 23 6.95 0.00 514 542 591
Total Equity & Noncontrolling Interests
201 100 365 1,187 1,685 743 772 573 387 588 489
Total Preferred & Common Equity
201 100 281 1,048 1,471 743 772 573 387 588 489
Total Common Equity
201 100 281 1,048 1,471 743 772 573 387 588 489
Common Stock
1,309 1,311 1,554 2,047 2,204 1,896 1,964 2,060 2,215 2,869 3,146
Retained Earnings
-1,095 -1,181 -1,241 -967 -708 -1,131 -1,160 -1,430 -1,796 -2,250 -2,631
Accumulated Other Comprehensive Income / (Loss)
-14 -30 -32 -32 -25 -21 -33 -57 -33 -31 -25

Quarterly Balance Sheets for Ionis Pharmaceuticals

This table presents Ionis Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
2,971 2,934 2,764 2,691 3,081 2,813 2,985 3,033 3,450 2,995 2,913
Total Current Assets
2,617 2,585 2,416 2,329 2,714 2,419 2,577 2,519 2,937 2,491 2,362
Cash & Equivalents
425 352 349 294 335 264 297 338 173 350 296
Short-Term Investments
1,961 1,884 1,857 1,785 2,149 1,881 1,993 1,902 1,746 1,705 1,588
Accounts Receivable
- - - - - - 53 25 74 59 88
Inventories, net
26 26 30 29 28 12 8.48 10 5.56 51 29
Other Current Assets
206 323 179 222 202 262 226 244 939 327 361
Plant, Property, & Equipment, net
92 71 73 76 83 103 112 106 142 155 162
Total Noncurrent Assets
263 278 275 286 285 291 296 408 371 348 389
Other Noncurrent Operating Assets
263 278 275 286 285 291 296 408 371 348 389
Total Liabilities & Shareholders' Equity
2,971 2,934 2,764 2,691 3,081 2,813 2,985 3,033 3,450 2,995 2,913
Total Liabilities
2,543 2,619 2,467 2,427 2,419 2,337 2,353 2,415 2,959 2,555 2,519
Total Current Liabilities
288 404 328 306 305 250 897 903 717 316 435
Short-Term Debt
- - 44 44 44 - 630 631 433 0.00 0.00
Accounts Payable
24 5.62 13 9.24 9.05 17 23 14 26 48 27
Accrued Expenses
105 119 106 114 124 103 99 99 127 116 116
Current Deferred Revenue
96 205 130 94 76 81 76 77 69 74 70
Current Deferred & Payable Income Tax Liabilities
25 31 2.21 0.28 0.04 0.13 0.08 0.10 2.87 2.88 0.11
Current Employee Benefit Liabilities
29 34 22 35 41 27 47 57 36 50 61
Other Current Liabilities
8.90 9.95 9.99 8.80 10 22 23 25 23 25 22
Total Noncurrent Liabilities
2,255 2,214 2,140 2,121 2,114 2,087 1,456 1,512 2,242 2,239 2,222
Long-Term Debt
1,299 1,230 1,189 1,191 1,192 1,195 566 567 1,321 1,323 1,324
Capital Lease Obligations
175 173 169 166 168 159 164 263 259 262 262
Noncurrent Deferred Revenue
254 249 215 189 174 141 125 108 76 63 49
Other Noncurrent Operating Liabilities
527 562 567 576 580 592 600 574 586 591 586
Total Equity & Noncontrolling Interests
428 315 297 264 662 476 632 618 491 440 394
Total Preferred & Common Equity
428 315 297 264 662 476 632 618 491 440 394
Total Common Equity
428 315 297 264 662 476 632 618 491 440 394
Common Stock
2,118 2,148 2,270 2,304 2,832 2,901 2,933 3,046 3,246 3,312 3,382
Retained Earnings
-1,639 -1,787 -1,939 -2,005 -2,145 -2,397 -2,273 -2,402 -2,724 -2,838 -2,948
Accumulated Other Comprehensive Income / (Loss)
-51 -46 -35 -35 -24 -29 -28 -26 -31 -34 -40

Annual Metrics And Ratios for Ionis Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Ionis Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
32.47% 31.40% 37.93% 16.63% 87.20% -35.04% 11.13% -27.53% 34.10% -10.48% 33.83%
EBITDA Growth
-89.90% 198.76% 158.62% -120.91% 2,633.64% -137.22% 101.67% -10,023.08% -45.79% -42.53% 18.98%
EBIT Growth
-58.73% 73.39% 198.26% -410.72% 693.30% -147.14% 76.80% -570.56% -26.80% -39.88% 16.19%
NOPAT Growth
-58.73% 73.39% 254.00% -297.67% 822.18% -138.83% 82.46% -1,258.88% 13.76% -34.31% 19.66%
Net Income Growth
-126.45% 31.58% 82.15% 2,093.74% 33.62% -267.01% 94.04% -843.18% -35.80% -23.92% 15.98%
EPS Growth
-124.24% 32.43% 130.00% 1,280.00% -8.21% -267.37% 93.71% -850.00% -34.74% -18.75% 21.71%
Operating Cash Flow Growth
236.12% -630.67% 255.34% 246.20% -42.67% -89.62% -14.19% -990.84% -12.08% -62.90% 46.38%
Free Cash Flow Firm Growth
-136.10% -877.58% 112.99% 598.20% -32.12% -25.47% -312.46% -112.73% 159.23% -365.34% 20.31%
Invested Capital Growth
-20.50% 69.53% 0.91% -295.19% 82.34% -433.22% 57.26% 49.03% -855.25% 39.57% 51.47%
Revenue Q/Q Growth
-10.50% 56.73% -3.51% 4.23% 36.73% -21.81% 22.66% -32.91% 28.07% -12.19% -2.40%
EBITDA Q/Q Growth
-165.52% 126.94% -51.17% 53.04% 136.21% -225.23% 100.97% -572.07% 11.58% -28.46% -40.49%
EBIT Q/Q Growth
-2,663.02% 86.60% -78.77% 21.56% 215.79% -255.42% 85.87% -2,637.52% 13.37% -28.71% -42.74%
NOPAT Q/Q Growth
-2,663.02% 86.60% -77.52% 21.67% -20.66% -286.89% 88.96% -2,495.45% 36.34% -28.27% -37.27%
Net Income Q/Q Growth
-721.33% 67.15% -121.39% 321.83% -28.55% -850.78% 95.30% -3,784.22% 10.54% -26.50% -48.78%
EPS Q/Q Growth
-716.67% 67.11% -67.39% 1,085.71% -40.44% -776.60% 95.38% -3,266.67% 10.80% -24.59% -40.83%
Operating Cash Flow Q/Q Growth
-83.66% 8.66% 37.22% 18.73% 88.56% -83.36% 141.11% -311.85% 43.11% -42.34% -8.73%
Free Cash Flow Firm Q/Q Growth
-132.33% -135.70% 187.27% -64.55% 326.45% 197.97% -367.71% -101,558.85% 666.96% -47.33% 5.88%
Invested Capital Q/Q Growth
-88.71% 56.43% -125.35% 48.96% 30.23% -415.54% 41.19% 67.88% 3.25% 27.38% 9.24%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 99.70% 99.61% 98.36% 98.66% 97.60% 98.84% 98.41% 98.31%
EBITDA Margin
-9.81% 7.38% 13.83% -2.48% 33.55% -19.23% 0.29% -39.67% -43.13% -68.66% -41.45%
Operating Margin
-26.70% -5.41% 6.04% -10.23% 32.59% -23.60% -3.72% -69.84% -44.91% -67.37% -40.45%
EBIT Margin
-26.70% -5.41% 3.85% -10.26% 32.53% -23.61% -4.93% -45.60% -43.12% -67.38% -42.07%
Profit (Net Income) Margin
-31.12% -16.20% -2.10% 35.85% 25.59% -65.78% -3.53% -45.92% -46.50% -64.37% -40.41%
Tax Burden Percent
100.42% 105.11% 64.33% -282.30% 84.80% 356.55% 98.11% 104.55% 109.68% 98.66% 100.47%
Interest Burden Percent
116.03% 285.05% -84.62% 123.72% 92.76% 78.16% 72.97% 96.31% 98.33% 96.84% 95.61%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 15.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-38.50% -40.22% -4.64% 27.70% 20.01% -39.52% -3.78% -40.12% -76.34% -93.10% -70.80%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-7.96% -2.17% 1.77% -3.09% 12.38% -6.12% -1.60% -10.41% -12.30% -15.85% -12.17%
Return on Assets (ROA)
-9.27% -6.49% -0.96% 10.77% 9.74% -17.06% -1.14% -10.48% -13.26% -15.15% -11.69%
Return on Common Equity (ROCE)
-38.50% -40.22% -3.80% 23.71% 17.55% -36.05% -3.78% -40.12% -76.34% -93.10% -70.80%
Return on Equity Simple (ROE_SIMPLE)
-43.97% -60.66% -3.84% 20.51% 19.53% -64.54% -3.71% -47.08% -94.72% -77.15% 0.00%
Net Operating Profit after Tax (NOPAT)
-53 -14 22 -43 310 -120 -21 -287 -248 -333 -267
NOPAT Margin
-18.69% -3.79% 4.23% -7.16% 27.64% -16.52% -2.61% -48.88% -31.44% -47.16% -28.31%
Net Nonoperating Expense Percent (NNEP)
-8.29% -15.98% -10.94% 27.56% -1.45% -26.49% -0.80% 2.32% -15.70% -13.66% -14.97%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - -14.84% -13.52% -16.66% -10.56%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.30% 0.39% 1.64% 1.34% 2.40% 1.16% 1.59% 1.69%
SG&A Expenses to Revenue
13.10% 13.04% 21.10% 40.79% 25.53% 48.59% 22.99% 25.59% 29.53% 37.93% 41.74%
R&D to Revenue
113.60% 92.37% 72.86% 69.14% 41.48% 73.37% 79.39% 141.84% 114.22% 127.85% 97.02%
Operating Expenses to Revenue
126.70% 105.41% 93.96% 109.93% 67.02% 121.96% 102.39% 167.43% 143.75% 165.78% 138.76%
Earnings before Interest and Taxes (EBIT)
-76 -20 20 -62 365 -172 -40 -268 -340 -475 -397
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-28 27 71 -15 377 -140 2.35 -233 -340 -484 -391
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
37.05 58.22 22.34 7.10 5.78 10.64 5.57 9.37 18.77 9.38 0.00
Price to Tangible Book Value (P/TBV)
40.99 73.20 24.24 7.26 5.88 11.05 5.57 9.37 18.77 9.38 0.00
Price to Revenue (P/Rev)
26.22 15.55 12.21 12.40 7.57 10.84 5.30 9.13 9.22 7.83 0.00
Price to Earnings (P/E)
0.00 0.00 18,142.24 27.17 30.55 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.01% 3.68% 3.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
24.76 15.11 11.54 10.23 6.22 9.49 4.22 8.07 8.09 6.57 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 204.86 83.42 0.00 18.54 0.00 1,457.68 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 299.43 0.00 19.12 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 272.93 0.00 22.50 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
332.51 0.00 34.06 10.17 20.20 192.86 111.13 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 280.60 41.56 69.68 92.71 0.00 0.00 31.88 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
1.94 5.03 1.62 0.54 0.46 1.22 1.61 2.38 3.74 2.39 4.17
Long-Term Debt to Equity
1.94 5.03 1.62 0.53 0.46 0.81 1.61 2.38 3.62 2.39 3.29
Financial Leverage
-1.85 -1.93 -1.28 -1.21 -1.10 -1.12 -1.23 -1.12 -1.58 -1.82 -1.42
Leverage Ratio
4.15 6.19 4.81 2.57 2.05 2.32 3.30 3.83 5.76 6.15 6.06
Compound Leverage Factor
4.82 17.66 -4.07 3.18 1.91 1.81 2.41 3.69 5.66 5.95 5.79
Debt to Total Capital
65.98% 83.41% 61.88% 35.09% 31.37% 55.01% 61.65% 70.39% 78.89% 70.52% 80.68%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.75% 0.00% 18.69% 0.00% 0.00% 2.42% 0.00% 17.07%
Long-Term Debt to Total Capital
65.98% 83.41% 61.88% 34.34% 31.37% 36.32% 61.65% 70.39% 76.47% 70.52% 63.61%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 8.79% 7.60% 8.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
34.02% 16.59% 29.33% 57.30% 59.93% 44.99% 38.35% 29.61% 21.11% 29.48% 19.33%
Debt to EBITDA
-13.99 18.20 8.34 -43.17 2.04 -6.48 528.36 -5.84 -4.25 -2.91 -5.22
Net Debt to EBITDA
14.89 -5.99 -6.05 97.02 -4.59 7.01 -372.40 2.68 2.61 1.84 1.63
Long-Term Debt to EBITDA
-13.99 18.20 8.34 -42.25 2.04 -4.28 528.36 -5.84 -4.12 -2.91 -4.12
Debt to NOPAT
-7.34 -35.47 27.28 -14.94 2.48 -7.55 -58.71 -4.74 -5.83 -4.23 -7.64
Net Debt to NOPAT
7.82 11.67 -19.78 33.57 -5.57 8.16 41.38 2.18 3.58 2.68 2.38
Long-Term Debt to NOPAT
-7.34 -35.47 27.28 -14.62 2.48 -4.98 -58.71 -4.74 -5.66 -4.23 -6.03
Altman Z-Score
5.26 3.68 3.90 3.52 4.61 3.05 2.01 1.63 1.60 0.96 0.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 18.13% 14.39% 12.28% 8.79% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.62 5.96 4.80 7.88 9.97 3.56 9.75 7.07 5.90 8.47 3.83
Quick Ratio
5.48 5.78 4.20 7.44 9.16 3.16 8.79 6.38 5.20 7.43 3.51
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-17 -163 21 148 100 75 -159 -337 200 -530 -423
Operating Cash Flow to CapEx
179.82% -972.46% 460.02% 3,415.51% 1,118.35% 102.20% 257.62% 0.00% -1,293.00% -1,106.33% -522.09%
Free Cash Flow to Firm to Interest Expense
-0.45 -3.81 0.47 3.30 1.27 7.85 -16.97 -41.55 2.45 -5.86 -4.67
Operating Cash Flow to Interest Expense
0.58 -2.62 3.89 13.46 4.40 3.77 3.29 -33.78 -3.78 -5.54 -2.97
Operating Cash Flow Less CapEx to Interest Expense
0.26 -2.89 3.05 13.07 4.00 0.08 2.02 -4.43 -4.07 -6.04 -3.53
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.30 0.40 0.46 0.30 0.38 0.26 0.32 0.23 0.29 0.24 0.29
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.93
Inventory Turnover
0.00 0.00 0.00 0.20 0.33 0.60 0.46 0.60 0.62 1.12 1.41
Fixed Asset Turnover
3.17 4.07 4.79 4.72 7.86 4.36 4.51 4.65 10.84 8.53 8.69
Accounts Payable Turnover
0.00 0.00 0.00 0.07 0.20 0.72 0.75 0.95 0.42 0.33 0.45
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.60
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 1,861.50 1,114.07 613.25 787.28 605.56 588.96 324.69 258.80
Days Payable Outstanding (DPO)
0.00 0.00 0.00 5,369.31 1,861.92 508.16 489.88 385.60 878.19 1,122.68 815.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 -3,507.81 -747.86 105.08 297.40 219.97 -289.23 -797.99 -525.60
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-214 -65 -65 -255 -45 -240 -103 -52 -500 -302 -147
Invested Capital Turnover
-1.45 -2.67 -7.93 -3.75 -7.48 -5.11 -4.73 -7.58 -2.85 -1.76 -4.21
Increase / (Decrease) in Invested Capital
-36 149 0.59 -191 210 -195 138 50 -447 198 155
Enterprise Value (EV)
7,024 5,632 5,932 6,134 6,981 6,922 3,423 4,740 6,372 4,630 0.00
Market Capitalization
7,439 5,797 6,277 7,437 8,497 7,906 4,297 5,365 7,258 5,520 0.00
Book Value per Share
$1.67 $0.82 $2.25 $7.62 $10.46 $5.32 $5.47 $4.03 $2.70 $3.73 $3.06
Tangible Book Value per Share
$1.51 $0.65 $2.08 $7.44 $10.28 $5.12 $5.47 $4.03 $2.70 $3.73 $3.06
Total Capital
590 600 958 1,829 2,455 1,652 2,012 1,935 1,831 1,996 2,531
Total Debt
389 501 593 642 770 909 1,241 1,362 1,445 1,407 2,042
Total Long-Term Debt
389 501 593 628 770 600 1,241 1,362 1,400 1,407 1,610
Net Debt
-415 -165 -430 -1,442 -1,730 -983 -874 -625 -886 -890 -636
Capital Expenditures (CapEx)
12 12 38 18 31 35 12 -238 24 45 51
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-116 -1.08 -98 -143 -52 -52 -10 -96 -93 13 -36
Debt-free Net Working Capital (DFNWC)
688 664 925 1,941 2,448 1,841 2,104 1,891 2,238 2,311 2,641
Net Working Capital (NWC)
688 664 925 1,928 2,448 1,532 2,104 1,891 2,194 2,311 2,209
Net Nonoperating Expense (NNE)
35 46 33 -258 23 359 7.47 -17 119 121 114
Net Nonoperating Obligations (NNO)
-415 -165 -430 -1,442 -1,730 -983 -874 -625 -886 -890 -636
Total Depreciation and Amortization (D&A)
48 48 51 47 11 32 42 35 -0.06 -9.05 5.87
Debt-free, Cash-free Net Working Capital to Revenue
-40.83% -0.29% -18.98% -23.80% -4.63% -7.10% -1.29% -16.30% -11.82% 1.89% -3.86%
Debt-free Net Working Capital to Revenue
242.55% 178.16% 179.92% 323.73% 218.03% 252.39% 259.67% 321.97% 284.15% 327.73% 279.85%
Net Working Capital to Revenue
242.55% 178.16% 179.92% 321.44% 218.03% 210.05% 259.67% 321.97% 278.52% 327.73% 234.08%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.74) ($0.72) $0.08 $2.09 $2.12 ($3.23) ($0.20) ($1.90) ($2.56) ($3.04) ($2.38)
Adjusted Weighted Average Basic Shares Outstanding
120.66M 123.75M 124.02M 132.32M 140.00M 139.61M 141.02M 141.85M 143.19M 149.51M 160.01M
Adjusted Diluted Earnings per Share
($0.74) ($0.72) $0.08 $2.07 $2.08 ($3.23) ($0.20) ($1.90) ($2.56) ($3.04) ($2.38)
Adjusted Weighted Average Diluted Shares Outstanding
120.66M 123.75M 126.10M 134.06M 142.87M 139.61M 141.02M 141.85M 143.19M 149.51M 160.01M
Adjusted Basic & Diluted Earnings per Share
($0.74) ($0.72) $0.08 $0.00 $2.12 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
119.72M 120.93M 125.40M 138.40M 139.22M 140.86M 141.69M 142.95M 145.75M 158.96M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-53 -14 22 -43 310 -120 -21 -287 -248 -333 -267
Normalized NOPAT Margin
-18.69% -3.79% 4.23% -7.16% 27.64% -16.52% -2.61% -48.88% -31.44% -47.16% -28.31%
Pre Tax Income Margin
-30.99% -15.42% -3.26% -12.70% 30.18% -18.45% -3.60% -43.92% -42.40% -65.25% -40.22%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-2.06 -0.47 0.44 -1.37 4.64 -18.10 -4.27 -32.98 -4.17 -5.25 -4.39
NOPAT to Interest Expense
-1.44 -0.33 0.49 -0.96 3.95 -12.67 -2.26 -35.35 -3.04 -3.68 -2.95
EBIT Less CapEx to Interest Expense
-2.38 -0.74 -0.40 -1.77 4.25 -21.79 -5.55 -3.63 -4.46 -5.75 -4.95
NOPAT Less CapEx to Interest Expense
-1.76 -0.60 -0.36 -1.35 3.55 -16.36 -3.54 -6.00 -3.33 -4.18 -3.52
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% -113.54% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -1.35% -18.89% 0.00% 11.97% -132.41% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Ionis Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Ionis Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - - 159,159,099.00 165,262,556.00 166,184,322.00
DEI Adjusted Shares Outstanding
- - - - - - - - 159,159,099.00 165,262,556.00 166,184,322.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - -0.58 -0.69 -0.66
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-8.45% 19.55% -7.21% -30.18% 10.14% 100.69% 17.12% -10.26% 86.98% -40.73% 54.88%
EBITDA Growth
-35.14% 14.08% -6.39% -1,510.86% 3.12% 307.21% -5.49% -100.93% 21.98% -167.45% 22.06%
EBIT Growth
-31.00% 17.13% -5.47% -1,800.15% 1.90% 313.68% -7.61% -108.78% 19.48% -172.40% 18.39%
NOPAT Growth
-30.98% 26.72% -3.76% -1,710.21% 1.77% 402.26% -7.75% -93.52% 20.04% -151.21% 18.40%
Net Income Growth
-14.86% 22.31% 4.70% -1,026.51% -2.90% 286.45% 8.45% -119.83% 37.03% -192.79% 14.49%
EPS Growth
-12.64% 25.00% 7.77% -1,000.00% 5.10% 255.56% 15.79% -104.55% 39.78% -198.57% 17.50%
Operating Cash Flow Growth
-11.90% -23.13% -5.47% -453.38% -0.56% 226.24% -14.30% -18.57% -425.83% 273.69% -36.50%
Free Cash Flow Firm Growth
-133.83% -147.09% -180.81% -162.13% -185.45% 120.39% -79.00% -10.97% -232.56% -1,534.08% 4.65%
Invested Capital Growth
-0.24% 14.43% 19.49% 39.57% 37.94% 28.10% 61.17% 51.47% 285.72% 89.99% 159.74%
Revenue Q/Q Growth
-63.18% 88.50% -40.59% 69.32% -41.91% 243.47% -65.33% 29.74% 21.03% 8.88% -9.42%
EBITDA Q/Q Growth
-2,029.23% 54.94% -120.92% 24.00% -28.06% 196.37% -212.47% -43.06% 49.68% 16.68% -29.96%
EBIT Q/Q Growth
-2,435.01% 56.12% -126.80% 24.68% -30.87% 195.58% -214.22% -44.38% 48.91% 14.06% -28.74%
NOPAT Q/Q Growth
-2,342.22% 55.80% -124.93% 25.45% -32.52% 236.03% -180.18% -33.88% 45.25% 12.89% -27.77%
Net Income Q/Q Growth
-1,441.65% 53.60% -112.00% 25.72% -40.81% 184.08% -204.09% -78.37% 59.66% -23.90% 4.08%
EPS Q/Q Growth
-1,533.33% 54.08% -111.11% 30.53% -40.91% 175.27% -214.29% -68.75% 58.52% -23.21% 4.35%
Operating Cash Flow Q/Q Growth
-556.22% 20.05% 4.08% -1.00% -29.82% 200.37% -186.85% -4.77% -475.72% 171.33% -131.73%
Free Cash Flow Firm Q/Q Growth
-121.33% -12.10% -76.55% -34.48% -7.25% 108.01% -1,649.65% 16.63% -221.43% 65.47% -3.03%
Invested Capital Q/Q Growth
6.30% 18.52% -0.57% 27.38% -4.30% 5.60% 45.69% 9.24% 499.11% -105.09% 424.16%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
98.20% 98.15% 99.20% 98.31% 98.89% 99.08% 98.51% 96.09% 98.79% 98.98% 98.63%
EBITDA Margin
-126.51% -30.24% -112.46% -50.48% -111.28% 31.22% -101.30% -111.69% -46.44% -35.53% -50.98%
Operating Margin
-125.12% -29.34% -111.09% -48.91% -111.59% 30.93% -102.21% -105.47% -47.72% -38.18% -53.85%
EBIT Margin
-124.89% -29.07% -110.99% -49.37% -111.23% 30.95% -101.98% -113.48% -47.90% -37.81% -53.73%
Profit (Net Income) Margin
-119.50% -29.42% -104.98% -46.05% -111.64% 27.33% -82.06% -112.82% -37.60% -42.79% -45.31%
Tax Burden Percent
100.05% 100.10% 97.49% 97.49% 100.08% 100.02% 100.17% 100.65% 100.24% 101.11% 99.87%
Interest Burden Percent
95.64% 101.10% 97.03% 95.69% 100.29% 88.29% 80.34% 98.77% 78.31% 111.92% 84.43%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% -0.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -261.82% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -258.85% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 186.59% 0.00% 0.00%
Return on Equity (ROE)
-98.27% -105.71% -73.38% -93.10% -118.62% -59.91% -40.04% -70.80% -75.23% -105.50% -108.05%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -196.00% 0.00% -677.27%
Operating Return on Assets (OROA)
-34.34% -8.35% -29.64% -11.62% -28.61% 10.30% -32.26% -32.81% -16.19% -11.05% -17.35%
Return on Assets (ROA)
-32.86% -8.45% -28.03% -10.84% -28.72% 9.09% -25.96% -32.62% -12.71% -12.51% -14.63%
Return on Common Equity (ROCE)
-98.27% -105.71% -73.38% -93.10% -118.62% -59.91% -40.04% -70.80% -75.23% -105.50% -108.05%
Return on Equity Simple (ROE_SIMPLE)
-129.76% -138.70% -54.16% 0.00% -96.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-105 -46 -104 -78 -103 140 -112 -150 -82 -72 -91
NOPAT Margin
-87.58% -20.54% -77.76% -34.24% -78.11% 30.93% -71.55% -73.83% -33.40% -26.72% -37.69%
Net Nonoperating Expense Percent (NNEP)
-4.25% -2.52% -3.81% -3.01% -5.54% -2.03% -1.77% -10.39% -2.96% -6.16% -3.43%
Return On Investment Capital (ROIC_SIMPLE)
- - - -3.89% -5.62% 7.02% -5.39% -5.93% -3.28% -3.54% -4.62%
Cost of Revenue to Revenue
1.80% 1.85% 0.80% 1.69% 1.11% 0.92% 1.49% 3.91% 1.21% 1.02% 1.37%
SG&A Expenses to Revenue
44.05% 28.91% 46.06% 38.87% 57.94% 20.05% 61.77% 64.03% 61.10% 56.13% 63.54%
R&D to Revenue
179.26% 98.59% 164.23% 108.35% 152.54% 48.11% 138.95% 137.53% 85.40% 81.03% 88.94%
Operating Expenses to Revenue
223.32% 127.49% 210.29% 147.22% 210.47% 68.15% 200.72% 201.56% 146.50% 137.15% 152.48%
Earnings before Interest and Taxes (EBIT)
-149 -65 -149 -112 -146 140 -160 -231 -118 -101 -130
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-151 -68 -150 -114 -146 141 -159 -227 -114 -95 -124
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
20.98 26.38 8.84 9.38 10.08 9.95 16.85 0.00 0.00 29.80 18.85
Price to Tangible Book Value (P/TBV)
20.98 26.38 8.84 9.38 10.08 9.95 16.85 0.00 0.00 29.80 18.85
Price to Revenue (P/Rev)
8.01 8.55 7.29 7.83 6.69 6.66 10.77 0.00 0.00 14.99 7.73
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 73.83
Enterprise Value to Revenue (EV/Rev)
6.97 7.72 5.95 6.57 5.58 5.68 9.96 0.00 0.00 14.45 7.42
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
4.73 5.31 2.12 2.39 2.85 2.15 2.36 4.17 4.10 3.60 4.03
Long-Term Debt to Equity
4.58 5.15 2.05 2.39 2.85 1.16 1.34 3.29 3.22 3.60 4.03
Financial Leverage
-2.29 -2.30 -1.95 -1.82 -2.07 -1.79 -1.45 -1.42 -0.72 -1.31 -1.06
Leverage Ratio
7.21 8.18 6.15 6.15 7.22 6.34 4.78 6.06 6.48 5.58 5.88
Compound Leverage Factor
6.90 8.27 5.97 5.88 7.24 5.60 3.84 5.98 5.07 6.25 4.96
Debt to Total Capital
82.54% 84.16% 67.96% 70.52% 74.01% 68.30% 70.27% 80.68% 80.38% 78.28% 80.12%
Short-Term Debt to Total Capital
2.61% 2.67% 2.15% 0.00% 0.00% 31.62% 30.35% 17.07% 17.27% 0.00% 0.00%
Long-Term Debt to Total Capital
79.93% 81.50% 65.81% 70.52% 74.01% 36.67% 39.92% 63.61% 63.10% 78.28% 80.12%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
17.46% 15.84% 32.04% 29.48% 25.99% 31.70% 29.73% 19.33% 19.62% 21.72% 19.88%
Debt to EBITDA
-3.70 -3.81 -3.73 -2.91 -2.83 -5.04 -5.25 -5.22 -5.61 -2.66 -2.83
Net Debt to EBITDA
2.12 1.84 2.86 1.84 1.65 3.44 2.80 1.63 -0.26 0.79 0.53
Long-Term Debt to EBITDA
-3.58 -3.69 -3.61 -2.91 -2.83 -2.71 -2.98 -4.12 -4.40 -2.66 -2.83
Debt to NOPAT
-5.15 -5.49 -5.42 -4.23 -4.10 -7.29 -7.50 -7.64 -8.16 -3.81 -4.01
Net Debt to NOPAT
2.95 2.65 4.16 2.68 2.39 4.98 4.00 2.38 -0.38 1.13 0.75
Long-Term Debt to NOPAT
-4.99 -5.31 -5.25 -4.23 -4.10 -3.92 -4.26 -6.03 -6.41 -3.81 -4.01
Altman Z-Score
1.54 1.80 1.52 1.36 1.05 1.68 2.26 0.00 0.00 2.80 1.33
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
7.37 7.61 8.91 8.47 9.66 2.87 2.79 3.83 4.10 7.89 5.43
Quick Ratio
6.73 6.79 8.15 7.43 8.57 2.61 2.51 3.51 2.78 6.70 4.53
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-103 -116 -205 -275 -295 24 -367 -306 -982 -339 -349
Operating Cash Flow to CapEx
-3,337.15% -1,923.00% -1,269.77% -455.50% -1,198.82% 1,229.89% -2,494.06% -646.76% -3,642.97% 3,516.98% -1,411.29%
Free Cash Flow to Firm to Interest Expense
-4.68 -5.09 -9.02 -12.05 -12.88 1.04 -16.54 -13.47 -43.66 -15.33 -39.91
Operating Cash Flow to Interest Expense
-6.78 -5.26 -5.07 -5.08 -6.58 6.65 -5.93 -6.07 -35.24 25.56 -20.49
Operating Cash Flow Less CapEx to Interest Expense
-6.98 -5.53 -5.47 -6.20 -7.12 6.11 -6.17 -7.01 -36.21 24.84 -21.94
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.28 0.29 0.27 0.24 0.26 0.33 0.32 0.29 0.34 0.29 0.32
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.93 0.00 15.69 17.00
Inventory Turnover
0.38 0.43 0.39 1.12 0.50 0.57 0.61 1.41 2.04 0.54 0.87
Fixed Asset Turnover
9.83 9.71 10.47 8.53 8.16 10.05 10.25 8.69 8.63 6.55 7.16
Accounts Payable Turnover
0.84 0.70 1.42 0.33 0.69 0.66 1.01 0.45 0.80 0.45 0.82
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 30.60 0.00 23.26 21.47
Days Inventory Outstanding (DIO)
963.06 856.04 944.74 324.69 723.98 645.78 602.94 258.80 178.63 675.83 419.17
Days Payable Outstanding (DPO)
432.91 524.78 256.20 1,122.68 529.42 556.20 362.15 815.00 455.34 803.33 444.83
Cash Conversion Cycle (CCC)
530.15 331.25 688.55 -797.99 194.57 89.58 240.79 -525.60 -276.72 -104.24 -4.20
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-508 -414 -416 -302 -315 -297 -161 -147 585 -30 96
Invested Capital Turnover
-1.53 -1.81 -1.72 -1.76 -1.74 -2.66 -3.35 -4.21 7.84 -5.34 -29.53
Increase / (Decrease) in Invested Capital
-1.20 70 101 198 193 116 254 155 900 268 258
Enterprise Value (EV)
5,415 6,279 4,779 4,630 4,005 5,359 9,633 0.00 0.00 12,634 7,123
Market Capitalization
6,220 6,957 5,857 5,520 4,796 6,288 10,412 0.00 0.00 13,104 7,420
Book Value per Share
$2.04 $1.81 $4.53 $3.73 $2.99 $3.97 $3.87 $3.06 $2.98 $2.66 $2.37
Tangible Book Value per Share
$2.04 $1.81 $4.53 $3.73 $2.99 $3.97 $3.87 $3.06 $2.98 $2.66 $2.37
Total Capital
1,699 1,665 2,067 1,996 1,830 1,993 2,079 2,531 2,504 2,025 1,980
Total Debt
1,402 1,401 1,405 1,407 1,354 1,361 1,461 2,042 2,013 1,585 1,587
Total Long-Term Debt
1,358 1,357 1,360 1,407 1,354 731 830 1,610 1,580 1,585 1,587
Net Debt
-804 -677 -1,078 -890 -791 -929 -779 -636 94 -469 -297
Capital Expenditures (CapEx)
4.49 6.23 9.06 25 13 12 5.27 21 22 16 13
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-74 -11 -30 13 23 20 6.28 -36 734 121 42
Debt-free Net Working Capital (DFNWC)
2,132 2,068 2,454 2,311 2,169 2,310 2,246 2,641 2,653 2,176 1,926
Net Working Capital (NWC)
2,088 2,023 2,409 2,311 2,169 1,680 1,616 2,209 2,220 2,176 1,926
Net Nonoperating Expense (NNE)
38 20 36 27 44 16 16 79 10 43 18
Net Nonoperating Obligations (NNO)
-804 -677 -1,078 -890 -791 -929 -779 -636 94 -469 -297
Total Depreciation and Amortization (D&A)
-1.94 -2.64 -1.97 -2.51 -0.07 1.23 1.07 3.64 3.61 6.10 6.69
Debt-free, Cash-free Net Working Capital to Revenue
-9.50% -1.36% -3.68% 1.89% 3.27% 2.12% 0.65% -3.86% 69.34% 13.85% 4.41%
Debt-free Net Working Capital to Revenue
274.58% 254.18% 305.55% 327.73% 302.35% 244.69% 232.32% 279.85% 250.70% 248.90% 200.63%
Net Working Capital to Revenue
268.86% 248.72% 300.01% 327.73% 302.35% 177.95% 167.07% 234.08% 209.83% 248.90% 200.63%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.98) ($0.45) ($0.95) ($0.66) ($0.93) $0.78 ($0.80) ($1.43) ($0.56) ($0.69) ($0.66)
Adjusted Weighted Average Basic Shares Outstanding
145.54M 145.96M 148.59M 149.51M 158.74M 159.14M 159.77M 160.01M 164.87M 165.42M 166.21M
Adjusted Diluted Earnings per Share
($0.98) ($0.45) ($0.95) ($0.66) ($0.93) $0.70 ($0.80) ($1.35) ($0.56) ($0.69) ($0.66)
Adjusted Weighted Average Diluted Shares Outstanding
145.54M 145.96M 148.59M 149.51M 158.74M 182.33M 159.77M 160.01M 164.87M 165.42M 166.21M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
145.97M 146.21M 157.90M 158.96M 159.16M 0.00 0.00 0.00 165.26M 166.18M 166.55M
Normalized Net Operating Profit after Tax (NOPAT)
-105 -46 -104 -78 -103 98 -112 -150 -82 -72 -91
Normalized NOPAT Margin
-87.58% -20.54% -77.76% -34.24% -78.11% 21.65% -71.55% -73.83% -33.40% -26.72% -37.69%
Pre Tax Income Margin
-119.44% -29.39% -107.69% -47.24% -111.56% 27.33% -81.93% -112.09% -37.51% -42.31% -45.37%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-6.75 -2.87 -6.54 -4.89 -6.38 6.15 -7.21 -10.17 -5.24 -4.58 -14.89
NOPAT to Interest Expense
-4.73 -2.03 -4.59 -3.39 -4.48 6.14 -5.06 -6.62 -3.65 -3.24 -10.45
EBIT Less CapEx to Interest Expense
-6.95 -3.15 -6.94 -6.01 -6.93 5.61 -7.45 -11.11 -6.21 -5.31 -16.35
NOPAT Less CapEx to Interest Expense
-4.94 -2.30 -4.98 -4.51 -5.03 5.60 -5.30 -7.56 -4.62 -3.96 -11.90
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Ionis Pharmaceuticals’ latest statements show improving revenue momentum and a substantial liquidity cushion, but the company remains structurally unprofitable and dependent on non-operating items, financing activity and milestone-related revenue. The figures below cover quarterly results from Q3 2022 through Q2 2026, with some earlier periods identified as restated.

  • Revenue has expanded over the multi-year period. Q2 2026 revenue reached $267.9 million, up from $188.4 million in Q2 2023 and $225.3 million in Q2 2024. Revenue also increased sequentially from $246.1 million in Q1 2026, although it remained well below the unusually strong $452.0 million reported for Q2 2025.
  • Gross margins remain exceptionally high. Q2 2026 gross profit was $265.2 million on $267.9 million of revenue, representing a gross margin of approximately 99%. This indicates that cost of revenue is relatively small compared with operating expenses.
  • Quarterly operating losses narrowed sequentially. The operating loss improved from $117.4 million in Q1 2026 to $102.3 million in Q2 2026. The latest loss was also substantially narrower than the $214.5 million operating loss in Q4 2025.
  • Liquidity improved during Q2 2026. Cash and equivalents increased to $350.1 million from $173.4 million in Q1, while short-term investments remained substantial at $1.70 billion. Combined cash and short-term investments totaled approximately $2.05 billion at June 30, 2026.
  • Near-term liquidity is strong relative to current obligations. Total current assets of $2.49 billion were nearly eight times total current liabilities of $315.6 million. Ionis also reported no short-term debt at the end of Q2 2026, compared with $432.5 million at the end of Q1.
  • Ionis generated positive operating cash flow in Q2 2026. Operating cash flow was $565.5 million, a sharp improvement from negative operating cash flow of $792.8 million in Q1 2026 and approximately $131 million of outflows in both Q3 and Q4 2025.
  • The Q2 cash-flow improvement was heavily influenced by non-cash adjustments. Ionis recorded $695.5 million of non-cash adjustments in Q2, which more than offset its $114.6 million net loss. Investors should not assume that the full $565.5 million of operating cash flow represents a recurring earnings run rate.
  • Investment activity is a major source of cash-flow volatility. Ionis frequently buys and sells short-term investments. In Q2 2026, investment sales and maturities exceeded purchases by approximately $41.7 million, producing positive investing cash flow of $23.5 million after capital expenditures and acquisitions.
  • Ionis has not demonstrated sustained profitability. The company reported net losses in Q3 2022, Q4 2022, every quarter supplied for 2023 and 2024, Q3 and Q4 2025, and both quarters of 2026. Q2 2026’s net loss was $114.6 million, or $0.69 per diluted share.
  • Research and development spending continues to exceed gross profit. Q2 2026 R&D expense was $217.1 million and SG&A expense was $150.4 million, resulting in total operating expenses of $367.5 million. The company’s pipeline investment may support future products, but it continues to generate sizeable operating losses in the present.

Balance-sheet trend: Total assets were $2.99 billion in Q2 2026, down from $3.45 billion in Q1 2026 and $3.08 billion in Q3 2024. The reduction from Q1 largely reflects a $611.6 million decline in other current assets, partially offset by higher cash. Total equity declined to $439.7 million from $662.5 million in Q3 2024, while retained earnings remained deeply negative at approximately $2.84 billion.

Debt remains a consideration. Ionis carried $1.32 billion of long-term debt and $262.5 million of capital lease obligations at the end of Q2 2026. The company repaid $432.6 million of debt during the quarter, which contributed to $412.3 million of negative financing cash flow. Although its investment portfolio provides significant liquidity, debt and lease obligations remain sizable compared with shareholders’ equity.

Overall, the statements present a mixed picture for retail investors: revenue is higher than it was several years ago, liquidity is substantial and debt repayment accelerated in Q2 2026. However, the business still produces recurring operating and net losses, and recent cash-flow gains were affected by large non-cash adjustments and investment transactions. Sustainable profitability will likely depend on continued commercial revenue growth and successful development of Ionis’ drug pipeline.

11/16/26 08:50 PM ETAI Generated. May Contain Errors.

Ionis Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Ionis Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Ionis Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$381.39 million in 2025, falling from -$88.28 million in 2015. The previous period was -$453.90 million in 2024. See where experts think Ionis Pharmaceuticals is headed by visiting Ionis Pharmaceuticals' forecast page.

Ionis Pharmaceuticals' total operating income in 2025 was -$381.68 million, based on the following breakdown:
  • Total Gross Profit: $927.80 million
  • Total Operating Expenses: $1.31 billion

Over the last 10 years, Ionis Pharmaceuticals' total revenue changed from $283.70 million in 2015 to $943.71 million in 2025, a change of 232.6%.

In the past 13 quarters, Ionis Pharmaceuticals' cash and equivalents has ranged from $173.38 million in Q1 2026 to $424.79 million in Q2 2023, and is currently $296.30 million as of their latest financial filing in Q3 2026.

Ionis Pharmaceuticals had total debt of $2.04 billion at the end of 2025, a 45.1% increase from 2024, and a 424.4% increase since 2015.

Over the last 10 years, Ionis Pharmaceuticals' book value per share changed from 1.67 in 2015 to 3.06 in 2025, a change of 82.9%.



Financial statements for NASDAQ:IONS last updated on 11/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners